267 related articles for article (PubMed ID: 20473593)
1. Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers.
Treliński J; Wierzbowska A; Krawczyńska A; Sakowicz A; Pietrucha T; Smolewski P; Robak T; Chojnowski K
Int J Hematol; 2010 Jun; 91(5):792-8. PubMed ID: 20473593
[TBL] [Abstract][Full Text] [Related]
2. Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2-V617F mutational status.
Treliński J; Wierzbowska A; Krawczyńska A; Sakowicz A; Pietrucha T; Smolewski P; Robak T; Chojnowski K
Leuk Lymphoma; 2010 Sep; 51(9):1727-33. PubMed ID: 20615083
[TBL] [Abstract][Full Text] [Related]
3. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
4. Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation.
Hattori N; Fukuchi K; Nakashima H; Maeda T; Adachi D; Saito B; Yanagisawa K; Matsuda I; Nakamaki T; Gomi K; Tomoyasu S
Int J Hematol; 2008 Sep; 88(2):181-188. PubMed ID: 18612778
[TBL] [Abstract][Full Text] [Related]
5. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
6. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera.
Karkucak M; Yakut T; Ozkocaman V; Ozkalemkas F; Ali R; Bayram M; Gorukmez O; Ocakoglu G
Mol Biol Rep; 2012 Sep; 39(9):8663-7. PubMed ID: 22722988
[TBL] [Abstract][Full Text] [Related]
8. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
9. VEGF-A, sVEGFR-1, and sVEGFR-2 in BCR-ABL negative myeloproliferative neoplasms.
Gadomska G; Stankowska K; Boinska J; Ślusarz R; Tylicka M; Michalska M; Jachalska A; Rość D
Medicina (Kaunas); 2017; 53(1):34-39. PubMed ID: 28237691
[TBL] [Abstract][Full Text] [Related]
10. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera.
Rottenstreich A; Kleinstern G; Krichevsky S; Varon D; Lavie D; Kalish Y
Eur J Intern Med; 2017 Jun; 41():49-54. PubMed ID: 27919526
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
Medinger M; Skoda R; Gratwohl A; Theocharides A; Buser A; Heim D; Dirnhofer S; Tichelli A; Tzankov A
Br J Haematol; 2009 Jul; 146(2):150-7. PubMed ID: 19466975
[TBL] [Abstract][Full Text] [Related]
12. Proteomic study of the impact of the JAK2-V617F mutation on the phenotype of essential thrombocythemia.
Mossuz P; Arlotto M; Hermouet S; Bouamrani A; Lippert E; Girodon F; Dobo I; Vincent P; Cahn JY; Berger F
Exp Hematol; 2008 Dec; 36(12):1642-7. PubMed ID: 18838204
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of interleukin-23 plasma levels in patients with polycythemia vera and essential thrombocythemia.
Gangemi S; Allegra A; Pace E; Alonci A; Ferraro M; Petrungaro A; Saitta S; Gerace D; Russo S; Penna G; Musolino C
Cell Immunol; 2012; 278(1-2):91-4. PubMed ID: 23121980
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry.
Abdulkarim K; Samuelsson J; Johansson P; Andréasson B
Eur J Haematol; 2017 Jun; 98(6):577-583. PubMed ID: 28251679
[TBL] [Abstract][Full Text] [Related]
15. Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications.
Pourcelot E; Trocme C; Mondet J; Bailly S; Toussaint B; Mossuz P
Exp Hematol; 2014 May; 42(5):360-8. PubMed ID: 24463275
[TBL] [Abstract][Full Text] [Related]
16. Dkk3 levels in patients with myeloproliferative neoplasms.
Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
[TBL] [Abstract][Full Text] [Related]
17. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.
Arellano-Rodrigo E; Alvarez-Larrán A; Reverter JC; Colomer D; Villamor N; Bellosillo B; Cervantes F
Am J Hematol; 2009 Feb; 84(2):102-8. PubMed ID: 19105233
[TBL] [Abstract][Full Text] [Related]
18. Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.
Patriarca A; Pompetti F; Malizia R; Iuliani O; Di Marzio I; Spadano A; Dragani A
Blood Transfus; 2010 Jan; 8(1):21-7. PubMed ID: 20104275
[TBL] [Abstract][Full Text] [Related]
19. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.
Lippert E; Boissinot M; Kralovics R; Girodon F; Dobo I; Praloran V; Boiret-Dupré N; Skoda RC; Hermouet S
Blood; 2006 Sep; 108(6):1865-7. PubMed ID: 16728702
[TBL] [Abstract][Full Text] [Related]
20. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status.
Finazzi G; Rambaldi A; Guerini V; Carobbo A; Barbui T
Haematologica; 2007 Jan; 92(1):135-6. PubMed ID: 17229651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
